Market revenue in 2023 | USD 244.7 million |
Market revenue in 2030 | USD 313.9 million |
Growth rate | 3.6% (CAGR from 2023 to 2030) |
Largest segment | Porcine |
Fastest growing segment | Bovine |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Porcine, Bovine |
Key market players worldwide | Pfizer Inc, Sanofi SA, Aspen Pharmacare Holdings Ltd, Fresenius SE & Co KGaA, Novartis AG ADR, GSK PLC ADR, Dr. Reddy’s Laboratories, LEO Pharma, B. Braun Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to heparin market will help companies and investors design strategic landscapes.
Porcine was the largest segment with a revenue share of 89.17% in 2023. Horizon Databook has segmented the Australia heparin market based on porcine, bovine covering the revenue growth of each sub-segment from 2018 to 2030.
The market in Australia is driven by growing prevalence of diseases such as DVT, PE, & cardiovascular disorders, and proactive government initiatives. For instance, the Australian Government of Health offers a list of heparin manufacturers with discounted prices.
In addition, local presence of key players, such as Hospira Pty Limited and Pfizer Australia Pty Ltd., is considered to be a major factor driving the market. According to the Australian Commission for Safety and Quality in Healthcare, in 2018, a significant population was at risk of venous thromboembolism and 10% of deaths in hospitals across Australia were attributed to the development of venous thromboembolism.
This annually costs the Australian Healthcare system $1.25 billion. Furthermore, as per Baker Heart and Diabetes Institute, over 330,000 Australians are suffering from atrial fibrillation, a disease whose prevalence is primarily attributed to diabetes.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia heparin market , including forecasts for subscribers. This country databook contains high-level insights into Australia heparin market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account